Forging ahead against MDR

The ability of cancer cells to pump out chemotherapeutics has made that capability an increasingly popular target for cancer drugs. However, in any given cancer cell, it is unknown which or how many human proteins might contribute to multidrug resistance (MDR).

Thus companies hoping to increase the efficacy of